Is Anthem Biosciences IPO a risky bet for investors? Posted by Able on July 13, 2025 Get link Facebook X Pinterest Email Other Apps Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Comments
Comments
Post a Comment